High-dose-rate interstitial brachytherapy as monotherapy in one fraction for the treatment of favorable stage prostate cancer: Toxicity and long-term biochemical results. Issue 3 (June 2016)

• Record Type: Journal Article
• Authors: Prada, Pedro J.; Cardenal, Juan; Blanco, Ana García; Anchuelo, Javier; Ferri, María; Fernández, Gema; Arrojo, Elisabeth; Vázquez, Andrés; Pacheco, Maite; Fernández, José
• Is Part Of: Radiotherapy and oncology. Volume 119:Issue 3(2016:Jun.)
• Page Start: 411
• Page End: 416
• Publication Date: 2016-06
• Subjects: AJCC American Joint Committee on Cancer -- BED Biologically effective dose -- CTAE v4.02 Common Toxicity Criteria for Adverse Event, version 4.02 -- CTV Clinical target volume -- D90 The dose that covers 90% volume of CTV -- D100 urethra Dose delivered to 100% of the urethra -- DVH Dose–volume histogram -- GI Gastrointestinal -- GU Genitourinary -- HDR High dose rate -- IMRT Intensity modulated radiotherapy -- LDR Low dose rate -- PSA Serum prostate-specific antigen -- PTV Planning target volume -- PD Prescribed dose -- SPSS Statistical analysis SPSS -- SD Standard deviations -- TFS Tumor-free survival -- TRUS The trans-rectal ultrasound -- V90-100-150-200 % of PTV receiving 90%, 100%, 150%, 200% of the PD) -- V120 urethra Volume that received a dose of 120% of the urethra; Brachytherapy -- High dose rate -- Prostate cancer -- Monotherapy; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2016.04.006
• Languages: English
• ISSNs: 0167-8140

Abstract

Abstract: Background: To evaluate acute and late genitourinary, the gastrointestinal toxicity and the long-term biochemical control after HDR monotherapy in one fraction (19 Gy). Patients and methods: Between April 2008 and October 2010, 60 consecutive patients were treated with favorable clinically localized prostate cancer; the median follow-up was 72 months (range 32–91). All patients received one implant and one fraction of HDR. Fraction dose was 19 Gy. Toxicity was reported according to the Common Toxicity Criteria for Adverse Event, Version 4.0 (CTAE v4.02) by the National Cancer Institute. Results: No intraoperative or perioperative complications occurred. Acute toxicity grade 2 or more was not observed in any patients. No chronic toxicity, such as incontinence, late urinary retention, urethral narrowing, rectal bleeding, anal ulcer and/or rectourethral fistula has been observed after treatment. The overall survival and failure in tumor-free survival (TFS) according to Kaplan–Meier estimates was 90% (±5%) and 88% (±5%) respectively at 6 years. The actuarial biochemical control was 66% (±6%) at 6 years. Conclusions: This protocol is feasible and very well tolerated with low genitourinary morbidity, no gastrointestinal toxicity but no the same level of LDR biochemical control at 6 years.